The long-term survival for patients with non-Hodgkin's lymphoma who have undergone autologous hematopoietic stem cell transplantation and subsequently relapsed has been poor. In a study by Vaishampayan et al.,
1 patients who relapsed after autologous bone marrow transplantation had a 3-year survival rate of 55% if they responded to further salvage therapy, whereas patients who did not respond had a 3-year survival of 14%. Vose et al. 2 found that patients with Hodgkin's disease who relapsed after an autologous transplant had a better median survival (i.e. 10.5 months) than patients with relapsed non-Hodgkin's lymphoma (i.e. 3 months). Treatments for patients relapsing after autologous transplant included further chemotherapy, radiation, combined chemotherapy and radiation, and a second transplant. 2 Only three of 74 patients with relapsed non-Hodgkin's lymphoma had remissions that lasted for 3 years. Two of these patients received radiation to a localized relapse and another had an allogeneic bone marrow transplant.
Alpha-interferon therapy has been used to treat several different types of malignancies and works through stimulation of natural killer cells, inducing major histocompatibility expression, and through antiproliferative effects. 3 Responses to single-agent alpha-interferon have been described in patients with relapsed B-and T-cell lymphoma. 4 We describe six patients with non-Hodgkin's lymphoma who had failed both standard therapy and autologous hematopoietic stem cell transplantation and then received alpha-interferon as further salvage therapy (see Table 1 ). All six patients were given a starting dose of 3-5 million units three times a week and then titrated up or down based on their side-effect profile. The patients with diffuse large B-cell lymphoma also received rituximab concomitant with the initiation of the alpha-interferon.
All three of the patients with diffuse large B-cell lymphoma responded to the alpha-interferon and rituximab, and were continued on alpha-interferon. One patient had a partial response that has lasted 13 months. Of the two patients with complete remissions, one has continued on single-agent alpha-interferon now for 5.5 years and remains in complete remission, and the other patient, with transformed diffuse large B-cell lymphoma, continues in remission but has had further 'maintenance' treatments with rituximab. Two of the three patients with T-/NK cell lymphoma responded to single-agent alpha-interferon. One patient with blastic NK cell lymphoma died within a few weeks of initiation of therapy and only received three doses of alpha-interferon. One patient with peripheral T-cell lymphoma unspecified was in complete remission for 48 months and then relapsed and succumbed to lymphoma.
Another patient with anaplastic large T-/null cell lymphoma that was ALK negative continues in complete remission at 31 months on maintenance alpha-interferon. Hypothyroidism and depression have both been noted as side effects of alpha-interferon therapy. 3, 5, 6 Three of the four patients described here who continue alive developed hypothyroidism and are receiving replacement therapy. One patient developed severe depression but responded to antidepression medications. One patient developed avascular necrosis of the femoral head.
Patients who fail autologous bone marrow transplant for aggressive non-Hodgkin's lymphoma have a poor prognosis and there is no standard treatment approach. While an occasional patient may benefit from allogeneic transplant, this is associated with a high mortality and many patients will not have donors or be too old for this treatment. Our findings suggest that alpha-interferon may have a beneficial role for some patients in this setting and deserves further study.
